ClinicalTrials.gg

How we know

Every link on this study, and who decided it

The study on the left, the conditions and drugs this site links it to, and on each link the judgments that made or checked it, by day and by judge. The top row is the record itself: each new version seen since tracking began. Dashed lines are links the registry record does not make itself. Select a link to see everything judged on it, or a mark for one decision with its reason and evidence.

Why Biliary Tract Neoplasms is on this study

  • ClinicalTrials.gov files the study under Biliary Tract Neoplasms.
  • GPT-6 Astra (Medium) judged the term right: what the study is about. Oct 20 (day only)
  • It is the study's main condition, by the main-condition rule: the study is compared with others under Biliary Tract Neoplasms.
4 links0 made here, not in the record8 judgments3 judges (the rules as one: Rule based)1 record change seen
GPT-6 Astra (Medium)Claude Opus 5.5Rule basedRecord updated on ClinicalTrials.gov
Oct 19Oct 26Nov 2Nov 9Nov 16TodayNCT05156788Tislelizumab(Anti PD-1),Lenvatinib and GEMOXTransformation in theTreatment of PotentiallyResectable, LocallyAdvanced Biliary TractCancerShanghai Zhongshan HospitalPhase 2 · active not recruitinRECORDThe record itselfVersions seen nightly since Sep 25, 2…›Nov 8 · ClinicalTrials.gov record · MeSH filing re-derivedMeSH filing re-derivedCONDITIONSBiliary Tract NeoplasmsThe registry's MeSH filing›Oct 20 · GPT-6 Astra (Medium) · RightAs of now · Rule based · Main conditionMain conditionDRUGSImmune checkpoint inhibitorsEntry “PD-1+Lenvatinib+GEMOX”, read b…›Nov 2 · Claude Opus 5.5 · TestedNov 18 · Rule based · TestedTestedLenvatinibEntry “PD-1+Lenvatinib+GEMOX”, read b…›Nov 2 · Claude Opus 5.5 · Tested · partnerNov 18 · Rule based · TestedTested · partnerGemcitabine-oxaliplatin reg…Entry “PD-1+Lenvatinib+GEMOX”, read b…›Nov 2 · Claude Opus 5.5 · TestedNov 18 · Rule based · TestedTested

Times are in your time zone; a day marked “day only” kept no time. The graph scrolls sideways on a narrow screen; every mark is also in the list below.

All judgments on this study

WhenLinkJudgeDecisionState
Oct 20Biliary Tract NeoplasmsGPT-6 Astra (Medium)RightCurrent
Nov 2Immune checkpoint inhibitorsClaude Opus 5.5TestedCurrent
Nov 2LenvatinibClaude Opus 5.5Tested · partnerCurrent
Nov 2Gemcitabine-oxaliplatin regimenClaude Opus 5.5TestedCurrent
Nov 8The record itselfClinicalTrials.gov recordMeSH filing re-derivedRecord change
Nov 18Immune checkpoint inhibitorsRule based · role ruleTestedAgrees
Nov 18LenvatinibRule based · role ruleTestedAgrees
Nov 18Gemcitabine-oxaliplatin regimenRule based · role ruleTestedAgrees
As of nowBiliary Tract NeoplasmsRule based · main-condition ruleMain conditionCurrent

The rules, in plain words

“Rule based” means one of these decided, not a model or a person. Each runs every night over every study.

Which drugs a study tests

Reads each treatment the study lists and the arms it is in. A drug only in the experimental arm is tested. A drug in every arm while something else changes between the arms is given beside it. A drug only in the control arm is the comparator. Placebo, procedures and usual care are known by name.

Where the whole record has been read, that reading's answer replaces the rule's.

What a study is mainly about

Starts from the first condition ClinicalTrials.gov files the study under. It moves to a narrower one only when the study's own title or listed conditions name it, and sets aside terms the registry often files by mistake. A study open to many cancers is not placed under one of them unless its title names it.

Checked against studies judged one by one; the study page says when it differs from the registry.